![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 31, 2006 5:38:23 PM
>>> Risk Factors in Clinical/Regulatory Outcomes
Not only is your observation regarding a partnership (or lack thereof) relevant vis-à-vis clinical trials, it is relevant for regulatory submissions too. However, the lack of a partnership is pretty far down on my list of risk elements. Before worrying about that, investors ought to mull some even greater risks.
For simplicity, I’m omitting such obvious risks as a clearly undersized trial or a regulatory submission based on pivotal trials that missed their goals. I.e., we are talking about the most important risks for a bona fide phase-3 trial or NDA/BLA.
The major risks in descending order of importance (IMO) are as follows:
1. Large insider selling around the time when data mature (e.g. PARS).
2. Poorly-understood disease, especially when there is no animal model. This includes such conditions as CFIDS, fibromyalgia, interstitial cystitis, irritable bowel syndrome, and the like.
3. Novel mechanism of action.
4. Non-disclosure of key details of the trial design and statistical-analysis plan. (This reared its head in NUVO’s recent failure in catheter occlusion.)
5. A high proportion of trial sites in third-world countries.
6. Failure to obtain a Special Protocol Assessment (FDA) or formal protocol guidance (EMEA).
7. Unduly complex trial design, which increases the likelihood of protocol violations.
8. Unusual primary endpoint (if there is no SPA).
9. Unusual scheduling of data reporting to investors (e.g. TELK).
10. Lack of a partner.
Feedback is welcome on any of the above! <<<
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM